Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
Launched by TELIK · Jul 10, 2006
Trial Information
Current as of May 02, 2025
Terminated
Keywords
ClinConnect Summary
This is a randomized, open label, multicenter, multinational Phase 3 study of TLK286 (Telcyta) in combination with liposomal doxorubicin (Doxil/Caelyx) as compared to the active control therapy with liposomal doxorubicin (Doxil/Caelyx) as second line therapy in patients with platinum refractory or resistant recurrent ovarian cancer. Patients will be randomly assigned to receive either TLK286 (Telcyta) in combination with liposomal doxorubicin (Doxil/Caelyx) or active control liposomal doxorubicin (Doxil/Caelyx).
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Are a woman 18 years of age or older
- • Have histologically or cytologically confirmed epithelial cancer or primary peritoneal cancer
- • Have platinum refractory or resistant cancer
- • Measurable disease according to radiographic RECIST criteria progression
- Exclusion Criteria:
- • Had treatment with first-line chemotherapy other than a platinum-containing regimen
- • Have clinically significant cardiac disease
- • Have any sign of intestinal obstruction interfering with nutrition
- • Are pregnant or lactating
- • Had prior treatment with liposomal doxorubicin
- • Had prior treatment with Telcyta
About Telik
Telik, a biopharmaceutical company, focuses on the discovery and development of innovative therapies for cancer and other serious diseases. Leveraging its proprietary drug development platform, Telik aims to identify and advance novel compounds that target critical pathways in tumor biology. With a commitment to scientific excellence and patient-centric approaches, the company strives to bring transformative treatments to market, addressing unmet medical needs and improving the quality of life for patients worldwide. Through rigorous clinical trials and collaborations, Telik is dedicated to fostering advancements in therapeutic options and enhancing outcomes in oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dundee, Scotland, United Kingdom
Abington, Pennsylvania, United States
Manhasset, New York, United States
Little Rock, Arkansas, United States
Orlando, Florida, United States
Antwerpen, , Belgium
Lexington, Kentucky, United States
New Hyde Park, New York, United States
Asheville, North Carolina, United States
Poway, California, United States
Arlington, Texas, United States
Toledo, Ohio, United States
Savannah, Georgia, United States
Little Rock, Arkansas, United States
Charlotte, North Carolina, United States
Charlotte, North Carolina, United States
San Diego, California, United States
Fresno, California, United States
Indianapolis, Indiana, United States
Roanoke, Virginia, United States
Concord, California, United States
Danville, Virginia, United States
Joliet, Illinois, United States
Shreveport, Louisiana, United States
Bethesda, Maryland, United States
Scottsbluff, Nebraska, United States
Cooperstown, New York, United States
Portland, Oregon, United States
Dunmore, Pennsylvania, United States
Columbia, South Carolina, United States
Antioch, California, United States
Walnut Creek, California, United States
Winston Salem, North Carolina, United States
Casa Grande, Arizona, United States
Honolulu, Hawaii, United States
Orlando, Florida, United States
Jacksonville, Florida, United States
Scottsbluff, Nebraska, United States
Charlotte, North Carolina, United States
Toledo, Ohio, United States
Rancho Mirage, California, United States
Omaha, Nebraska, United States
Concord, California, United States
Newport Beach, California, United States
San Leandro, California, United States
Hollywood, Florida, United States
Jacksonville, Florida, United States
Pembroke Pines, Florida, United States
Flossmoor, Illinois, United States
Joliet, Illinois, United States
Kankakee, Illinois, United States
Morris, Illinois, United States
Metairie, Louisiana, United States
St. Louis, Missouri, United States
Babylon, New York, United States
Lake Success, New York, United States
Charlotte, North Carolina, United States
Lexington, North Carolina, United States
Fargo, North Dakota, United States
Columbus, Ohio, United States
Portland, Oregon, United States
Pittsburgh, Pennsylvania, United States
Upland, Pennsylvania, United States
Charleston, South Carolina, United States
Columbia, South Carolina, United States
Trophy Club, Texas, United States
Kortrijk, , Belgium
Leuven, , Belgium
Belo Horizonte, Mg, Brazil
Cerqueria Cesar, Sao Paulo, Brazil
Rua Dona Siilveria, Sao Paulo, Brazil
London, England, United Kingdom
Patients applied
Trial Officials
Gail L. Brown, MD, MBA
Study Director
Telik
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials